The Friend helper murine leukemia virus (Fr-MuLV) and the Moloney murine leukemia virus (Mo-MuLV) give rise to different diseases after injection into newborn NFS mice: Fr-MuLV induces primarily erythroleukemia, whereas MoMuLV gives rise to T-cell lymphomas (14, 19, 21, 22) . Analysis of recombinant viruses revealed that a strong determinant of the distinct pathogenic phenotypes of the two viruses is located within the U3 region of their long terminal repeats, suggesting that the disease specificity might be related to tissue-specific regulation of viral transcription (4, 5) . We have shown, using a transient expression assay, that the U3 region of each virus contains a transcriptional enhancer; the two enhancers have different cell type specificities, and these specificities correlate with the pathogenic properties of the viruses, although not explaining them completely (2) . In particular, while both enhancers are equally active in erythroid cells, they behave very differently in T-lymphoid cells, where the Mo-MuLV enhancer is approximately 30-fold more active than the Fr-MuLV enhancer. The nucleotide sequences of the enhancer regions of the two viruses are highly homologous (2, 8, 9) . A reasonable hypothesis is that some of the differences between the two nucleotide sequences are responsible for the different activities of the two enhancers in T-lymphoid cells because they are located within a cis-acting element(s) which regulates the activity of the enhancer specifically in this cell type. In the present work, we have attempted to address this question by the construction of a series of mutant enhancers.
To measure enhancer activity, we used the vector pTK-CAT, in which the cat gene (7) is under the control of the herpes simplex thymidine kinase (tk) gene promoter (12) . (Fig. 1A) . Sau3A-BssHII DNA fragments carrying either the Fr-MuLV or Mo-MuLV enhancer were cloned into the pTK-CAT plasmid, 5' to the tk promoter, in their natural orientations relative to their own promoters (Fig. 1B) . These constructions and the pTK-CAT plasmid were transfected in parallel into human hematopoietic cell lines, and chloram-phenicol acetyltransferase (CAT) activities were determined as described (2) . We used two erythroid cell lines, K562 (1, 11) and PUTKO (15) , and two T-lymphoid cell lines, JM-1 (16) and MOLT-4 (13) . Comparison of the values obtained with the enhancer-containing plasmids with those obtained with the enhancerless plasmid pTK-CAT provided an estimate of the activity of the enhancer in each cell line ( Table  1) . The results obtained with the tk promoter-based vector were essentially identical to those obtained previously with a simian virus 40-based vector (2) . In the present experiments, we also included another construct, referred to as pMSV-1 and carrying a Sau3A-XbaI DNA fragment containing the Moloney murine sarcoma virus (Mo-MuSV) enhancer (12) (Fig. 1B) . Within this region, the nucleotide sequence of the Mo-MuSV genome was almost identical to that of the Mo-MuLV genome (Fig. 2) . Indeed, we found that the Mo-MuSV enhancer behaved similarly to the Mo-MuLV enhancer and was active in both erythroid and T-lymphoid cells (Table 1) .
We decided to use the Mo-MuSV plasmid as a basis for constructions designed to define the sequence element(s) responsible for the difference in activity in T cells between the Fr-MuLV enhancer and the Mo-MuSV or Mo-MuLV enhancer. Figure 2 (Fig. 1B, plasmid pMSV-2 ). Since the EcoRV sites were located within each direct repeat, the replacement involved exactly a permuted repeat (Fig. 2) . While the activity of the hybrid enhancer was similar to that of the wild-type Mo-MuSV enhancer in erythroid cells, it was approximately 15-fold lower in T cells (Table 1) . Therefore, these data demonstrated the existence of sequences within the direct repeats important for activity in T cells.
To verify whether levels of CAT activity were indeed reflecting levels of mRNA transcribed from the tk promoter, we analyzed the relative amounts of TK-CAT RNA present in transfected cells. This was done by using an SP6 RNA mapping procedure (23) , with a uniformly 32P-labeled complementary SP6 RNA probe spanning the 5' end of the gene (Fig. 3B) . Hybridization of an excess of the probe to TK-CAT mRNA correctly initiated from the tk promoter is expected to protect a 210-nt RNA fragment from RNase digestion (12) (Fig. 3) . Figure 3 shows the results of such an analysis performed on RNA extracted from transfected PUTKO and JM-1 cells. With PUTKO cells transfected with "Enhancer activities in erythroid and T-lymphoid cell lines were determined. The activity of each enhancer was defined for each cell line as the ratio of CAT activities obtained with the enhancer-containing plasmid and the enhancerless plasmid pTK-CAT. The values shown are the means of the values obtained in at least two independent experiments involving duplicate plates, as described (2) . The figures in parentheses are the extreme values observed. N.D., Not done.
pMSV-1 and pMSV-2, a doublet of similar intensity was observed, corresponding to fragments about 205 and 209 nt long (lanes 3 and 4). These protected fragments were therefore likely to correspond to correctly initiated mRNA molecules, the occurrence of two bands possibly being due to heterogeneity in the RNase digestion. With cells transfected with pTK-CAT, such bands were observed only after a long exposure of the film (lane 5, and data not shown). The increase in RNA level due to the presence of the enhancer was approximately 80-fold, as measured by scanning of autoradiograms with a densitometer. In JM-1 cells, correctly initiated RNA was only detected after transfection with plasmid pMSV-1, which contained the wild-type Mo-MuSV enhancer (lanes 6 and 7). Quantitation indicated that the level of correctly initiated TK-CAT RNA in JM-1 cells was at least fivefold higher with pMSV-1 than with pMSV-2. These differences were not due to differential RNA recovery, since the same RNA preparations were used to detect alpha-actin mRNA by Northern (RNA) blotting and yielded signals of similar intensities (data not shown). These results indicated that the wild-type Mo-MuSV and hybrid FrMuLV/Mo-MuSV enhancers increased cat expression by activation of transcription from the tk promoter and that the relative levels of CAT activity reflected the relative amounts of RNA transcribed from the tk promoter. The comparison in Fig. 4 of the nucleotide sequences of the internal EcoRV fragments of Mo-MuSV and Fr-MuLV enhancers indicates that they diverged in two regions, which will be referred to as A (5' region) and B (3' region). To determine which region of divergence was responsible for the different phenotypes of the Mo-MuSV and hybrid enhancers, we constructed plasmids pMSV-3 and pMSV-4, in which region A or region B was converted to the Fr-MuLV version, respectively (Fig. 4) . Analysis of these constructs indicated that mutations in region A as well as in region B reduced the activity of the Mo-MuSV enhancer in T cells (Fig. 4) . The effect of each mutation was more limited than the double mutation (compare pMSV-3 or pMSV-4 with pMSV-2, Fig. 4) .
The mutation introduced in region A consisted of a cluster of four point mutations and did not involve any change in spacing. This suggested that this mutation affected directly a cis-acting element modulating the activity of the enhancer. Analysis of the nucleotide sequence in region A revealed the presence of the sequence 5'-TGCCCCNNNTCAG-3', which was also present in region B in the reverse orientation (Fig.  4) . The two copies of this sequence will be referred to as A and B. The sequence A was mutated to 5'-GGCCCCN NNCCGG in the Fr-MuLV enhancer. Interestingly, sequence B was affected by the mutation in region B (Fig. 4) . This raised the possibility that two copies of the same regulatory element were present within the EcoRV fragment and that they consisted of sequences A and B. To test this possibility, we constructed plasmid pMSV-5, which was derived from plasmid pMSV-3 by conversion of sequence B to the Fr-MuLV version of sequence A, a change involving three point mutations (Fig. 4) . Indeed, we found that pMSV-5 behaved like pMSV-2: the introduction of the three point mutations in sequence B further reduced the activity of the enhancer in T cells. The fact that the introduction of the same point mutations in sequence A or B affected the activity of the enhancer similarly strongly supports the idea that the two sequences play a similar role and regulate the activity of the enhancer in T cells.
To localize more precisely the regulatory element and in particular to evaluate the contribution of the conserved sequences 5'-TGCCCC-3' and 5'-TCAG-3' within sequence A, we constructed plasmids pMSV-6 and pMSV-7, derived from pMSV-4, in which only 2 nt were mutated in region A (Fig. 4) . The mutation of 2 nt within the TCAG sequence did not affect the activity of the enhancer (Fig. 4 , compare pMSV-4 and pMSV-7, pMSV-2 and pMSV-6). In contrast, the mutation of 2 nt within and immediately upstream from the TGCCCC sequence had the same effect as the mutation of the 4 nt (Fig. 4 , compare pMSV-2, pMSV-4, pMSV-6, and pMSV-7). This suggested that the TGCCCC sequence, or a portion of it, was part of the regulatory element. The different mutant enhancers had similar activities in erythroid cells, although pMSV-3 showed a slightly lower activity. This indicated that the DNA element evidenced by our experiments not only regulated enhancer activity but did so in a tissue-specific manner.
In conclusion, we have localized critical nucleotide differences between Mo-MuSV and Fr-MuLV enhancer sequences which are responsible for the difference in activity of the two enhancers in T-lymphoid cells. This allowed the identification of a cis-acting regulatory element. This element, in its Mo-MuSV version, includes either part of or the entire sequence 5'-TGCCCC-3' and will be referred to as the TGC element. The 5'-TGCCCC sequence was observed four times within the two direct repeats of the Mo-MuSV en- Table 1 , except that CAT activities were normalized to the levels of growth hormone expressed from a plasmid carrying the human growth hormone gene (17) which was cotransfected with the CAT plasmids.
hancer, one of the copies carrying a point mutation (Fig. 2) . Two copies were present within each repeat, in opposite orientation (Fig. 4) . Another copy of the sequence was found within the Mo-MuSV U3 region, 3' to the enhancer DNA fragment used in the present study (position -122). All the copies of the TGCCCC sequence, including the 3' one, were mutated in the Fr-MuLV U3 region. It appears from our data that the two copies of the TGC element in which we introduced mutations acted independently: each copy contributed to the activity of the enhancer by a factor of approximately four. We have not tested the possible contribution of the other TGC elements. It is tempting to speculate that the TGC element acts as a binding site for a cellular transcriptional regulatory trans-acting factor present in T cells. This factor might also be present in other cell types. Recently, it has been reported that a factor present in mouse B-lymphoid cells binds to at least part of the TGCCCC sequence in vitro (20) .
The similar behavior of Mo-MuSV and Mo-MuLV enhancers (Table 1) suggests that the TGC element is also responsible for the activity of the Mo-MuLV enhancer in T cells. It is interesting that in the case of the Mo-MuLV enhancer, two of the copies of the TGCCCC sequence located within the direct repeats were mutated, compared with one in the case of the Mo-MuSV. Since the disease specificities of Mo-MuLV and Fr-MuLV have been shown to be determined by the U3 region of the long terminal repeat (4, 5) and to correlate with the activity of the enhancer (2), our data suggest that the TGC element is one of the determinants of the disease specificity of the virus. In particular, it is likely that the presence of one or several intact copies of this element in the U3 region is required for efficient replication of the virus in T cells and ultimately for generation of T-cell lymphoma. Our conclusions are consistent with recent data from Li and colleagues (10), who localized the major determinant of the disease specificity of Mo-MuLV and Fr-MuLV within the direct repeats of the enhancer.
